TOM1

Across TCGA pan-cancer cohorts, TOM1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TOM1 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TOM1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TOM1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where TOM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.240	0.776	.005	30	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	14	view →
LSCC	DFS	Median	III,IV	0.437	0.851	.012	12	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.452	.018	8	view →
HNSC	OS	Median	All	1.000	0.449	.023	6	view →
GBM	DFS	Quartile	All	0.594	0.858	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TOM1–LUAD (OS)

Open the LUAD breakdown →